The US Department of Justice has filed a consent decree in the district court of Maryland for the Indian pharmaceutical major, Ranbaxy aiming to resolve the four-year long investigation by the US Food and Drug Administration (FDA).

The consent decree required the company to make fundamental changes to its plants in India and in the US for complying with the standards in the US. The US Justice Department filed the consent decree in court yesterday requiring the Indian firm to comply with US manufacturing standards and ensure integrity of data in its plants in India as well as the US.

The shares of Indian pharmaceutical major, Ranbaxy fell about 7 per cent following the filing of a consent decree in a US court, which required the company to make fundamental changes to its plants in India and in the US.

The US Justice Department filed the consent decree in court yesterday requiring the Indian firm to comply with US manufacturing standards and ensure integrity of data in its plants in India as well as the US.

Indian pharmaceutical major, Ranbaxy Laboratories has signed a consent decree with the US Food and Drugs Administration [FDA] in order to make it possible to sell drugs produced at its plans in India, which are facing a fan in the US.

Ranbaxy has said in a filing to the stock exchanges that it is setting aside $500 million in a provision to meet the possible expense in the case involving investigation by the US Department of Justice.

Indian pharmaceutical major, Ranbaxy Laboratories Ltd has said in a filing to the stock exchanges that it is setting aside $500 million in a provision to meet the possible expense in the case involving investigation by the US Department of Justice.

"The company intends to make a provision of $500 million in connection with the investigation by the US Department of Justice, which the company believes will be sufficient to resolve all potential civil and criminal liability," the filing read.

India pharmaceutical major, Ranbaxy might see a delay in its launch of generic Lipitor drug as it is yet to get an approval from the US Food and Drugs Administration [FDA] to launch the product in the US market.

The US patent of Pfizer for the `Lipitor' medicine has expired today. Ranbaxy and Watson Pharmaceuticals are the only two firms licensed to sell the product in the next six months. Watson is expected to launch the product this week but Ranbaxy might see a delay as it does not have necessary approval.

India's top drug maker by sales, Ranbaxy Laboratories has reported a loss of Rs464-crore in the second quarter of the financial year primarily due to huge losses incurred in the foreign exchange market.

The company lost Rs 651 crore during the quarter to foreign currency fluctuations. The profitability took a hit due to mark-to-market (MTM) requirements for long dated derivative transactions and foreign currency denominated loans.

It has been reported that Ranbaxy Laboratories will soon be launching its cholesterol drug Lipitor. It is believed that the drug will be out by 30th November. Following the revelation of the new drug, its shares on the BSE rose by 4% today.

It has been informed that the Ranbaxy is yet to take Food and drug Administration’s approval before launching its Lipitor, which is a generic version of Lipitor. The drug is available in the US where it is sold annually for $7 billion.

Technical analyst Jatinder Sharma has maintained 'buy' rating on Ranbaxy Laboratories Limited, stock to attain a target of Rs 495.

According to analyst, the investors can buy the stock above Rs 475 with trailing stop loss of Rs 462.

The stock of the company, on April 25, closed at Rs 474.40 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 17.68 and 26.73 respectively.

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Technical analyst Rajesh Satpute has maintained 'buy' rating on Ranbaxy Laboratories Limitedstock with targets of Rs 476 and 504.

Mr. Kulkarni said that the stock can be bought with a stop loss of Rs 454.

The analyst also said that the said target can be attained within a period of 3-4 trading sessions.

The stock of the company, on April 07, closed at Rs 463 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 17.68 and 26.43 respectively.

Mylan has sued the US FDA for inaction and failure to disclose the status on 180-day marketing exclusivity relevant to Ranbaxy's ANDA on generic Lipitor.

Technical analyst D Prasad has maintained 'buy' rating on Ranbaxy Laboratories Limited stock to achieve a target of Rs 485.

According to analyst, the investors can buy the stock above Rs 467 with a stop loss of Rs 457.

Mr. Prasad said that the said target can be attained in 2-3 trading sessions.

The stock of the bank, on March 17, closed at Rs 467.35 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 17.68 and 26.59 respectively.

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Technical Analyst Salil Sharma has maintained 'buy' rating on Ranbaxy Laboratories Limited stock to achieve a target of Rs 485.

Mr. Sharma said that the investors can buy the stock above Rs 465 with a stop loss of Rs 456.

The analyst said that the said target can be achieved in 2-3 trading sessions.

The stock of the company, on March 15, closed at Rs 468.55 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 17.68 and 25.95 respectively.

Technical analyst Somil Mehta of Sharekhan has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a short term target of Rs 505.

According to analyst, the stock can be purchased with a stop loss of Rs 440.60.

Today, the stock of the company opened at Rs 464 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 24.34 and 18.71 respectively.

Leading pharmaceutical firm Ranbaxy has announced its financial results for last year. The company has said that it has posted an impressive five-fold net profit rise in the year under review. As per the company officials, the net profit of the company has surged up to Rs 1,497 crore for the year that ended on 31st December, 2010. The company had posted a net profit of Rs 296.5 crore in the preceding year i. e. 2009.

Technical analyst Rajesh Satpute has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a short term target of Rs 596.

The analyst said that the stock can be purchased with a stop loss of Rs 576.

The stock of the company, on December 27, closed at Rs 574.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 24.34 and 23.91 respectively.

Technical analyst Atul Badkar of Edelweiss Securities has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a target of Rs 610.

The analyst said that the stock can be purchased with a stop loss of Rs 550.

Mr. Badkar said that the said target can be attained within a period of 8-10 trading sessions.

The stock of the company, on December 22, closed at Rs 569.10 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Technical analyst Salil Sharma has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a target of Rs 580.

According to analyst, the investors can buy the stock with a stop loss of Rs 560.

The stock of the company, on December 06, closed at Rs 568.25 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 24.34 and 23.38 respectively.

Technical analyst D Prasad has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a target of Rs 600.

According to analyst, the investors can buy the stock above Rs 581 with a stop loss of Rs 569.

Mr. Prasad said that the stock can achieve the target within a period of 2-3 trading sessions.

The stock of the company, on December 01, closed at Rs 576.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 634.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 24.34 and 24.10 respectively.

Stock market analyst Hemant Kale of Maia Financial Services has maintained 'hold' rating on Ranbaxy Laboratories Limited stock to achieve a target of Rs 650.

According to analyst, the said target can be bought with a stop loss of Rs 570.

Today, the stock of the company opened at Rs 615 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 620.55 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 27.74 and 22.34 respectively.

During the July-September quarter, Ranbaxy's shares continued to perform brilliantly.

Stock market analyst Salil Sharma has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a target of Rs 580.

The strict stop loss for the stock will be Rs 553.

The stock of the company, on Sep 21, closed at Rs 561.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 566 and a low of Rs 350 on BSE.

Current EPS & P/E ratio stood at 27.74 and 20.12 respectively.